boots semaglutide Weight loss jab is now available in Wegovy | Boots Online Doctor
Description
Indias GLP-1 and GIP market is no longer an emerging story
Background The worldwide rise in overweight and obesity is paralleled by an increasing prevalence of type-2 diabetes
Key Highlights: Abbott will exclusively distribute and market Extension in India Available in 0.25 mg, 0.5 mg, and 1 mg doses (same as Ozempic) Manufacturing remains with Novo Nordisk Positioned to be competitively priced Comes months after Ozempics India launch This follows Novo Nordisks earlier partnership with Emcure Pharma to commercialize PoviZtra (a semaglutide brand) in India
The 20mg pen-format listing may be reviewed alongside standard vial products and higher contained pen formats
Learn more about its role in diabetes management.
